About AFT Pharmaceuticals
AFT Pharmaceuticals is a publicly listed company based in Auckland (New Zealand) founded in 1997. Proprietary and in-licensed pharmaceutical products are developed and distributed. The company has 119 employees. AFT Pharmaceuticals has completed 3 acquisitions, including Angelini Pharma, Expanscience and Therabel. Its website aftpharm.com draws about 21 thousand monthly visits. AFT Pharmaceuticals offers products and services including Maxigesic and Generic Drugs. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified. Its legal entity is AFT Pharmaceuticals Limited.
Company details
Founded in 1997 and based in Auckland, New Zealand, operations in the pharmaceutical sector are conducted. Proprietary and in-licensed products, including patented, branded, and generic drugs, are developed and distributed. Research and development efforts are directed toward innovative solutions for unmet healthcare needs, with analgesics and eye care items featured in the portfolio. Out-licensing agreements are utilized for international distribution.
- Headquarters Auckland, New Zealand
- Employees 119
- Stage Public
- SectorsHealthcare
- Website category Health · Pharmacy
- Website aftpharm.com
- Social LinkedIn Facebook Instagram YouTube
- Legal Name Aft Pharmaceuticals Ltd.
- Annual Revenue$145.99 M (USD)22.44as on Mar 31, 2026
- Net Profit$8.44 M (USD)23.14as on Mar 31, 2026
- EBITDA$16.36 M (USD)45.95as on Mar 31, 2026
- Latest Funding Round$48.24M (USD), Post-IPO
Jun 2020
- InvestorsCRG
& 1 more
- Employee Count119
- Investments & AcquisitionsAngelini Pharma
& 2 more
Products & Services of AFT Pharmaceuticals
AFT Pharmaceuticals offers a comprehensive portfolio of products and services, including Maxigesic and Generic Drugs.
Maxigesic is developed as a combination analgesic that is distributed through licensing agreements for pain management purposes.
Generic drugs are offered as part of a portfolio that includes in-licensed and patented options for various health needs.
Apps and channels of AFT Pharmaceuticals
its YouTube channel AFT Pharmaceuticals has 395 subscribers and 30 videos.
Videos from AFT Pharmaceuticals
The most watched videos on AFT Pharmaceuticals's YouTube channel, AFT Pharmaceuticals (395 subscribers). Click a video to play it here.
More on AFT Pharmaceuticals.
Funding Insights of AFT Pharmaceuticals
- Total Rounds 4
- Last Round Post-IPO — $48.24M
- First Round $12M
(May 2014)
- Investors Count 2
All 4 funding rounds of AFT Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in AFT Pharmaceuticals
AFT Pharmaceuticals has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include CRG and Milford Asset Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
CRG is recognized as a premier healthcare investment partner. | crglp.com | Houston, United States | ||
Milford Asset Management is engaged in investment and wealth management. | milfordasset.com | Auckland, New Zealand |
Investor details for AFT Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AFT Pharmaceuticals
20 people are tracked at AFT Pharmaceuticals (5 in leadership, 4 in board & advisors, 11 in team); the tracked headcount is 119.
| Name | Role | Group |
|---|---|---|
Scott Crawford | General Manager - Promoted Products | Leadership |
Ioana Stanescu | Head of Drug Development | Leadership |
Hartley Atkinson | Director | Leadership |
Geoffrey Taylor | Head Of Global Logistics & Inventory | Leadership |
Lorraine Corr-Poppleton | Head Of Promoted Products Asia | Leadership |
David Flacks | Chairman | Board & advisors |
Doug Wilson | Independent Director | Board & advisors |
Jon Lamb | Independent Director | Board & advisors |
Ted Witek | Independent Non-Executive Director | Board & advisors |
Vladimir Ilievski | Regulatory Affairs Manager | Team |
Grace Mikhail Radu | GP Sales Representative | Team |
Giselle Morrison | Business Operations And Sales Support Manager | Team |
Lee-Anne Gorringe | Inventory & Logistics Manager | Team |
Frances Cruickshank | Senior Territory Manager / Optical Accounts Manager | Team |
Naresh Ganti | Territory Manager | Team |
Daniel Shalhoub | Sales Manager - AU Nth | Team |
Philip T. Kendall Ma. | Account Manager Hospital Specialist Rx Business - QLD + Northern NSW | Team |
Alba Luz Galeano | Regulatory Affairs Associate | Team |
Lisa Chang | Senior Clinical And Pharmacovigilance Associate | Team |
Maggie Sun | Global Category Manager | Team |
Complete people profiles for AFT Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of AFT Pharmaceuticals
AFT Pharmaceuticals is a publicly listed company on the NZX with ticker symbol AFT in New Zealand, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 Dec 2015
- Listed onASX: AFP · NZX: AFT
- Listed entityAFT Pharmaceuticals Ltd.
- Exchange sectorHealth technology
- ISINNZAFTE0001S4
- Share price4.49 NZD (-2.18% on the day) · 2026-10-14
- Market capitalisation481,374,690.00 NZD
- Price to earnings32.0
- EPS (diluted, trailing year)0.14 NZD
- Dividend yield0.64%
- Volume (last session)33,234
Financials of AFT Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 254.7M NZD | 14.7M NZD | 28.6M NZD |
| 2024 | 208.0M NZD | 12.0M NZD | 19.6M NZD |
| 2023 | 195.4M NZD | 15.6M NZD | 25.7M NZD |
| 2022 | 156.6M NZD | 10.7M NZD | 21.4M NZD |
| 2021 | 130.3M NZD | 19.9M NZD | 21.2M NZD |
Detailed financial statements for AFT Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AFT Pharmaceuticals
AFT Pharmaceuticals has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Angelini Pharma, Expanscience and Therabel.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Dermo-cosmetic products, pharmaceutical drugs, and cosmetic active ingredients are developed. | expanscience.com | Paris, France | 1950 | Jan 2018 | •••• | |
Pharmaceutical products are provided through industry partnerships for distribution. | therabel.com | Breda, Netherlands | 1945 | May 2017 | •••• | |
Manufacturer and developer of active ingredients, branded drugs, medical products and dietary supplements | angelinipharma.com | Rome, Italy | 1919 | Jan 2017 | •••• |
Complete acquisition details for AFT Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of AFT Pharmaceuticals
7 dated milestones of AFT Pharmaceuticals across 23 years, from founding to its latest funding, stage changes and deals.
- Founded AFT Pharmaceuticals is founded.
- Funding First funding round of $12.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Angelini Pharma.
- Acquisition Acquires Therabel.
- Acquisition Acquires Expanscience.
- Funding Latest funding round, Post-IPO, of $48.2M.
Web traffic of AFT Pharmaceuticals
The website of AFT Pharmaceuticals (aftpharm.com) receives about 20.6K visits a month and ranks #1,239,364 among all websites worldwide, #2,010 in Pharmacy.
- Monthly visits20.6K
▼ 13.1% vs previous month
- Unique visitors11.1K
per month
- Global rank#1,239,364
among all websites
- Category rank#2,010
Health · Pharmacy
- Bounce rate41%
- Pages per visit1.5
- Average visit11 sec
- DevicesDesktop 29% · Mobile 71%
Websites whose visitors overlap most with AFT Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
gastrostop.com.au | gastrostop.com.au | 100% | #1,833,362 | – | |
| advacarepharma.com | 93% | 680.7K | #373,777 | View details | |
pharmacydirect.com.au | pharmacydirect.com.au | 70% | #88,735 | – | |
aelo.com.au | aelo.com.au | 68% | #2,057,271 | – | |
medcart.com.au | medcart.com.au | 60% | #1,053,340 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for AFT Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aft Pharmaceuticals
Complete news archive for AFT Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AFT Pharmaceuticals
AFT Pharmaceuticals was founded in 1997 and raised its 1st funding round 17 years after it was founded.
AFT Pharmaceuticals is headquartered in Auckland, New Zealand.
AFT Pharmaceuticals has 119 employees.
Annual revenue of AFT Pharmaceuticals is $145.99M as on Mar 31, 2026.
Founded in 1997 and based in Auckland, New Zealand, operations in the pharmaceutical sector are conducted. Proprietary and in-licensed products, including patented, branded, and generic drugs, are developed and distributed. Research and development efforts are directed toward innovative solutions for unmet healthcare needs, with analgesics and eye care items featured in the portfolio. Out-licensing agreements are utilized for international distribution.
AFT Pharmaceuticals offers Maxigesic and Generic Drugs.
Yes, AFT Pharmaceuticals is publicly traded on NZX under the ticker symbol AFT.
AFT Pharmaceuticals has made 3 acquisitions, including Angelini Pharma, Expanscience, and Therabel.
AFT Pharmaceuticals has 2 investors. Key investors include CRG, and Milford Asset Management.
AFT Pharmaceuticals operates through Aft Pharmaceuticals Limited.